Common markers of proliferation.

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res (2008) 6.63

When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer (2009) 5.86

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer (2007) 4.44

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35

The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res (2008) 3.80

Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res (2009) 3.45

Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol (2011) 3.33

Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc Natl Acad Sci U S A (2007) 3.20

Matrix density-induced mechanoregulation of breast cell phenotype, signaling and gene expression through a FAK-ERK linkage. Oncogene (2009) 3.17

Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One (2008) 2.66

Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet (2013) 2.59

A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res (2011) 2.26

Global mitotic phosphorylation of C2H2 zinc finger protein linker peptides. Cell Cycle (2011) 2.25

Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res (2010) 2.15

A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res (2008) 2.09

p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol (2008) 2.04

Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res (2006) 2.03

RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle (2010) 1.96

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science (2016) 1.95

The DREAM complex: master coordinator of cell cycle-dependent gene expression. Nat Rev Cancer (2013) 1.93

Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. J Natl Cancer Inst (2011) 1.92

Mechanical signaling through the cytoskeleton regulates cell proliferation by coordinated focal adhesion and Rho GTPase signaling. J Cell Sci (2011) 1.90

Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat (2011) 1.89

A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med (2009) 1.84

Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue. Breast Cancer Res Treat (2009) 1.83

Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer. Am J Pathol (2008) 1.82

T cell fate and clonality inference from single-cell transcriptomes. Nat Methods (2016) 1.81

Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics (2011) 1.67

A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol (2009) 1.60

Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol (2011) 1.59

Ki-67 acts as a biological surfactant to disperse mitotic chromosomes. Nature (2016) 1.56

Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms. PLoS Comput Biol (2015) 1.55

Genome-wide transcriptional analysis of the human cell cycle identifies genes differentially regulated in normal and cancer cells. Proc Natl Acad Sci U S A (2008) 1.53

Wnt3a reestablishes osteogenic capacity to bone grafts from aged animals. J Bone Joint Surg Am (2013) 1.52

Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists. BMC Med Genomics (2008) 1.43

The A2b adenosine receptor protects against vascular injury. Proc Natl Acad Sci U S A (2008) 1.39

Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. BMC Cancer (2008) 1.37

Microarray based diagnosis profits from better documentation of gene expression signatures. PLoS Comput Biol (2008) 1.33

A biophysical indicator of vaso-occlusive risk in sickle cell disease. Sci Transl Med (2012) 1.32

Differential gene expression profile of retinoblastoma compared to normal retina. Mol Vis (2010) 1.31

Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol (2010) 1.29

Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol (2008) 1.26

Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol (2013) 1.26

Biomolecular events in cancer revealed by attractor metagenes. PLoS Comput Biol (2013) 1.26

Transcriptional changes associated with breast cancer occur as normal human mammary epithelial cells overcome senescence barriers and become immortalized. Mol Cancer (2007) 1.24

Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo. Oncogene (2012) 1.20

An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Res (2009) 1.19

Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression. Tumour Biol (2010) 1.16

Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma. Mol Cancer Res (2008) 1.16

Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types. Br J Cancer (2008) 1.15

Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Res (2008) 1.15

Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer. Proc Natl Acad Sci U S A (2012) 1.14

In vitro and in vivo analysis of B-Myb in basal-like breast cancer. Oncogene (2008) 1.13

The σ2 receptor: a novel protein for the imaging and treatment of cancer. J Med Chem (2013) 1.13

Simultaneous Multiplexed Measurement of RNA and Proteins in Single Cells. Cell Rep (2015) 1.10

MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene (2013) 1.09

Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity. Br J Cancer (2013) 1.09

Mixed effects modeling of proliferation rates in cell-based models: consequence for pharmacogenomics and cancer. PLoS Genet (2012) 1.08

MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics (2010) 1.08

The molecular diversity of Luminal A breast tumors. Breast Cancer Res Treat (2013) 1.07

Genome-wide expression patterns of invasion front, inner tumor mass and surrounding normal epithelium of colorectal tumors. Mol Cancer (2007) 1.06

Inhibition of CBF/NF-Y mediated transcription activation arrests cells at G2/M phase and suppresses expression of genes activated at G2/M phase of the cell cycle. Nucleic Acids Res (2006) 1.05

YB-1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst (2011) 1.04

Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. Br J Cancer (2009) 1.04

Proliferation and tissue remodeling in cancer: the hallmarks revisited. Cell Death Dis (2012) 1.03

A tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancer. PLoS One (2011) 1.03

The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proc Natl Acad Sci U S A (2011) 1.02

Lentivirus-mediated silencing of Tiam1 gene influences multiple functions of a human colorectal cancer cell line. Neoplasia (2006) 1.01

Genetic differences in transcript responses to low-dose ionizing radiation identify tissue functions associated with breast cancer susceptibility. PLoS One (2012) 1.00

The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele. Cell Death Differ (2014) 0.99

Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. Breast Cancer Res (2012) 0.99

Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors. Cancers (Basel) (2015) 0.99

A comparison of oncogene-induced senescence and replicative senescence: implications for tumor suppression and aging. Age (Dordr) (2014) 0.98

Do two machine-learning based prognostic signatures for breast cancer capture the same biological processes? PLoS One (2011) 0.98

The ubiquitin-conjugating enzyme E2-EPF is overexpressed in primary breast cancer and modulates sensitivity to topoisomerase II inhibition. Neoplasia (2007) 0.98

Reduced expression of a gene proliferation signature is associated with enhanced malignancy in colon cancer. Br J Cancer (2008) 0.96

Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks. Nucleic Acids Res (2016) 0.93

Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells. World J Surg Oncol (2013) 0.93

A gene sets approach for identifying prognostic gene signatures for outcome prediction. BMC Genomics (2008) 0.93

Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target. Cancer Res (2010) 0.93

Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Br J Cancer (2014) 0.92

Chemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resection. J Transl Med (2013) 0.92

A novel measure of chromosome instability can account for prognostic difference in multiple myeloma. PLoS One (2013) 0.91

Poly-omic prediction of complex traits: OmicKriging. Genet Epidemiol (2014) 0.91

Homeostatic mass control in gastric non-neoplastic epithelia under infection of Helicobacter pylori: an immunohistochemical analysis of cell growth, stem cells and programmed cell death. Acta Histochem Cytochem (2008) 0.91

Independent and functional validation of a multi-tumour-type proliferation signature. Br J Cancer (2012) 0.90

Immutable functional attributes of histologic grade revealed by context-independent gene expression in primary breast cancer cells. Cancer Res (2009) 0.90

Chromatin CKAP2, a new proliferation marker, as independent prognostic indicator in breast cancer. PLoS One (2014) 0.89

Association of TGFβ signaling with the maintenance of a quiescent stem cell niche in human oral mucosa. Histochem Cell Biol (2016) 0.89

Increased mitochondrial function downstream from KDM5A histone demethylase rescues differentiation in pRB-deficient cells. Genes Dev (2015) 0.87

Genomic distance entrained clustering and regression modelling highlights interacting genomic regions contributing to proliferation in breast cancer. BMC Syst Biol (2010) 0.87

Evidence for OTUD-6B participation in B lymphocytes cell cycle after cytokine stimulation. PLoS One (2011) 0.86

A signature-based method for indexing cell cycle phase distribution from microarray profiles. BMC Genomics (2009) 0.86

Wnt signaling potentiates nevogenesis. Proc Natl Acad Sci U S A (2013) 0.86

Digital holographic microscopy for non-invasive monitoring of cell cycle arrest in L929 cells. PLoS One (2014) 0.85

Module organization and variance in protein-protein interaction networks. Sci Rep (2015) 0.85

A multi-gene transcriptional profiling approach to the discovery of cell signature markers. Cytotechnology (2010) 0.85

Influence of fatty acid diets on gene expression in rat mammary epithelial cells. Physiol Genomics (2009) 0.84

Using the information embedded in the testing sample to break the limits caused by the small sample size in microarray-based classification. BMC Bioinformatics (2008) 0.84

A signature inferred from Drosophila mitotic genes predicts survival of breast cancer patients. PLoS One (2011) 0.83

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09

Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01

Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22

Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68

Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell (2002) 17.32

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res (2004) 16.51

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12

Concordance among gene-expression-based predictors for breast cancer. N Engl J Med (2006) 13.50

Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A (2002) 12.68

The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45

The somatic genomic landscape of glioblastoma. Cell (2013) 11.73

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res (2007) 11.56

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res (2010) 10.90

Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49

MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res (2010) 9.80

Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70

A custom microarray platform for analysis of microRNA gene expression. Nat Methods (2004) 9.44

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95

Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A (2010) 7.70

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res (2008) 7.39

Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007) 7.08

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol (2006) 6.86

Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods (2005) 6.23

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71

Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68

Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet (2011) 5.62

Deconstructing the molecular portraits of breast cancer. Mol Oncol (2010) 5.37

Adjustment of systematic microarray data biases. Bioinformatics (2004) 5.22

Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20

Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol (2006) 4.84

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol (2009) 4.66

A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res (2010) 4.61

Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol (2012) 4.14

Mutation of GATA3 in human breast tumors. Oncogene (2004) 3.92

Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell (2004) 3.91

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85

Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res (2008) 3.83

The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res (2008) 3.80

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell (2012) 3.77

A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37

Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell (2009) 3.36

EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics (2007) 3.35

Molecular portraits and the family tree of cancer. Nat Genet (2002) 3.28

Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res (2008) 3.25

Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet (2006) 3.19

Integrated study of copy number states and genotype calls using high-density SNP arrays. Nucleic Acids Res (2009) 3.09

Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res (2010) 3.04

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00

Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res (2006) 2.95

Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol (2009) 2.88

A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res (2009) 2.84

AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest (2006) 2.74

Statistical modeling for selecting housekeeper genes. Genome Biol (2004) 2.73

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat (2011) 2.73

Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res (2005) 2.73

Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One (2008) 2.66

A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res (2013) 2.63

Gene expression patterns associated with p53 status in breast cancer. BMC Cancer (2006) 2.61

Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist (2013) 2.55

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45

Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest (2010) 2.38

Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol (2011) 2.38

A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. PLoS One (2009) 2.29

RNA expression analysis of formalin-fixed paraffin-embedded tumors. Lab Invest (2007) 2.25

Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat (2011) 2.23

FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. Clin Cancer Res (2007) 2.22

CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis. Cancer Cell (2009) 2.17

A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med (2006) 2.16

Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res (2010) 2.15

Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol (2007) 2.12

Mammary development meets cancer genomics. Nat Med (2009) 2.04

PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics (2012) 2.01

PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res (2009) 2.01

Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues. Clin Chem (2007) 2.01

Defining the cellular precursors to human breast cancer. Proc Natl Acad Sci U S A (2011) 2.01

Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci U S A (2011) 2.01

Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res (2004) 2.01

Universal Reference RNA as a standard for microarray experiments. BMC Genomics (2004) 2.00

Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat (2011) 1.96

Merging two gene-expression studies via cross-platform normalization. Bioinformatics (2008) 1.93

Mitochondrial Hep27 is a c-Myb target gene that inhibits Mdm2 and stabilizes p53. Mol Cell Biol (2010) 1.86

A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med (2009) 1.84

Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst (2012) 1.81

Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest (2008) 1.80

Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A (2011) 1.78

Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS One (2012) 1.76

Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res (2012) 1.74

Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. PLoS One (2012) 1.72

The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov (2013) 1.71

MAP3K4/CBP-regulated H2B acetylation controls epithelial-mesenchymal transition in trophoblast stem cells. Cell Stem Cell (2011) 1.71

TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Res Treat (2011) 1.68

Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics (2011) 1.67

Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther (2006) 1.64

Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol (2010) 1.55

Prediction of toxicant-specific gene expression signatures after chemotherapeutic treatment of breast cell lines. Environ Health Perspect (2004) 1.55

Interactions with fibroblasts are distinct in Basal-like and luminal breast cancers. Mol Cancer Res (2010) 1.53

ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex. Cancer Cell (2007) 1.53

A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res (2012) 1.52